Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cfg-920 SCHEMBL29450382 | 1.00 | CYP17A1 (0.69) | CYP17A1 | |
| SCHEMBL3784144 | 0.87 | CYP17A1 (0.54) | CYP17A1 | |
| SCHEMBL3787367 | 0.86 | CYP17A1 (0.53) | CYP17A1 | |
| SCHEMBL3782127 | 0.84 | CYP17A1 (0.49) | CYP17A1 | |
| SCHEMBL3787427 | 0.83 | CYP17A1 (0.48) | CYP17A1 | |
| SCHEMBL3784539 | 0.83 | CYP17A1 (0.72) | CYP17A1 | |
| SCHEMBL3782489 | 0.82 | CYP17A1 (0.49) | CYP17A1 | |
| SCHEMBL13735832 | 0.82 | CYP17A1 (1.00) | CYP17A1 | |
| SCHEMBL3778129 | 0.82 | CYP17A1 (0.71) | CYP17A1 | |
| SCHEMBL3791096 | 0.82 | CYP17A1 (0.48) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265300-B1 | COMPOSITION COMPRISING A 17 A-HYDROXYLASE/C17,20 LYASE (CYP17A1) INHIBITOR AND AN AKT INHIBITOR | NOVARTIS AG (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20250090514-A1 | METHOD OF TREATING CANCER | Laekna Limited (HK) | 2025-03-20 | — | — | US | claimed |
| US-20250017947-A1 | COMBINATION | NOVARTIS AG (CH) | 2025-01-16 | — | — | US | claimed |
| EP-4392036-A1 | SELECTIVE ISONITRILE INHIBITORS OF CYTOCHROME P450 SUBTYPES | Brandeis University (US) | 2024-07-03 | — | — | EP | claimed |
| EP-4265300-A2 | COMBINATION | Novartis AG (CH) | 2023-10-25 | — | — | EP | claimed |
| CN-116688124-A | Inhibition of estrogen response related pathway and uses thereof | 中国科学院分子细胞科学卓越创新中心 | 2023-09-05 | — | — | CN | claimed |
| EP-4199926-A1 | COMBINATIONAL DRUG ANTICANCER THERAPIES | Plexxikon Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| CN-116322690-A | Combination pharmaceutical anticancer therapies | 奥普纳生物有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-11628176-B2 | Combinational drug therapies | Opna Bio SA (CH) | 2023-04-18 | — | — | US | claimed |
| EP-4009969-A1 | METHOD OF TREATING CANCER | Laekna Limited (CN) | 2022-06-15 | — | — | EP | claimed |
| US-20210038578-A1 | METHOD OF TREATING CANCER | Laekna Limited (HK) | 2021-02-11 | — | — | US | claimed |
| US-20150157645-A1 | COMBINATION OF A 17-ALPHA-HYDROXYLASE (C17,20-LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-06-11 | — | — | US | claimed |
| EP-2858631-A1 | COMBINATION OF A 17 -ALPHA -HYDROXYLASE (C17, 20 - LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE | Novartis AG (CH) | 2015-04-15 | — | — | EP | claimed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | claimed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | claimed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | claimed |
| WO-2013184621-A1 | COMBINATION OF A 17 -ALPHA -HYDROXYLASE (C17, 20 - LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE | NOVARTIS AG (CH) | 2013-12-12 | — | — | WO | claimed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | claimed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | claimed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038578-A1 | METHOD OF TREATING CANCER | KLK3, ACP3, AR | CYP17A1 11/4885 |
| US-20250017947-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | CYP17A1 1/4885 |
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CYP17A1 1/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CYP17A1 1/4885 |
| US-20150157645-A1 | COMBINATION OF A 17-ALPHA-HYDROXYLASE (C17,20-LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE | CYP17A1, HSD17B7, HSD17B3 | CYP17A1 1/4885 |
| US-20250090514-A1 | METHOD OF TREATING CANCER | KLK3, ACP3, AR | CYP17A1 11/4885 |
| US-11628176-B2 | Combinational drug therapies | PARP6, AR, PARP3 | CYP17A1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.